About Tempo Bioscience
Tempo Bioscience is a company based in San Francisco (United States) founded in 2013 by Angela Huang. It operates as a B2B. Tempo Bioscience offers products and services including iAstroâ„¢, TempoATPâ„¢, iCardioâ„¢, and TempoCALâ„¢. Tempo Bioscience operates in a competitive market with competitors including Kiyatec, Cellply, Lucid Scientific, DiscoverX and CytoTronics, among others.
- Headquarter San Francisco, United States
- Founders Angela Huang
- SectorsHealthcare
- Website tempobioscience.com
- Social LinkedIn X
Products & Services of Tempo Bioscience
Tempo Bioscience offers a comprehensive portfolio of products and services, including iAstro™, TempoATP™, iCardio™, and TempoCAL™.
iPSC-derived astrocytes for neurological disease research.
Assay for measuring ATP metabolism in cells.
iPSC-based cardiomyocytes for cardiac research studies.
Tool for calcium signaling analysis in biological systems.
People of Tempo Bioscience
1 people are tracked at Tempo Bioscience (1 in leadership).
| Name | Role | Group |
|---|---|---|
Angela Huang | Founder, President | Leadership |
Complete people profiles for Tempo Bioscience
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Competitors of Tempo Bioscience
Tempo Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kiyatec, Cellply, Lucid Scientific, DiscoverX and CytoTronics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kiyatec.com | 2005 | Pendleton, United States | $29.49M | – | Kiyatec is focused on revolutionizing cancer care through predictive platforms. | |
| cellply.com | 2013 | Bologna, Italy | $8.05M | – | Developer of in-vitro diagnostic products for the detection of cancer | |
| lucidsci.com | 2012 | Atlanta, United States | $12.73M | – | Real-time cell analyzers are developed for oxygen consumption monitoring. | |
| discoverx.com | 2000 | Birmingham, United Kingdom | $13.4M | – | Develops cell-based assays and provides services for drug discovery and development. | |
| cytotronics.com | 2015 | Boston, United States | $22.75M | 22 | Cell-based assays for drug discovery are developed via CMOS platform. | |
| saguarobio.com | 2020 | Quebec, Canada | $4.1M | 4 | 3D cell culture products are developed for drug discovery applications. | |
| remedyplan.com | 2011 | – | $24.7M | – | Metastatic cancer properties are targeted by Remedy Plan's containment therapy. | |
| historx.com | 2001 | Branford, United States | $13.26M | – | Tissue-based diagnostic solutions for research and clinical pathology markets | |
| panomics.com | 2000 | Fremont, United States | $48.6M | – | Cell-based assays and instruments are developed for multiplexed molecular measurements. | |
| indigobiosciences.com | 2005 | State College, United States | $1.28M | 17 | Nuclear receptor and in vitro toxicology solutions are provided. |
Detailed competitors of Tempo Bioscience
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Tempo Bioscience
The website of Tempo Bioscience (tempobioscience.com) receives about 6.1K visits a month.
- Monthly visits6.1K
▲ 3.9% vs previous month
Websites whose visitors overlap most with Tempo Bioscience. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| mandalmed.com | 99% | 1.3K | #14,142,095 | View details | |
| ligandal.com | 97% | – | – | View details | |
| ossiumhealth.com | 96% | 7.5K | #3,051,166 | View details | |
| altrubio.com | 96% | 2.3K | #7,696,601 | View details | |
| synthexlabs.com | 95% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 22 similar websites and full traffic analytics for Tempo Bioscience
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 22 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Tempo Bioscience
Complete news archive for Tempo Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Tempo Bioscience
10 companies that operate in the same segment as Tempo Bioscience (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 300 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Tempo Bioscience
Tempo Bioscience was founded in 2013.
Tempo Bioscience is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Tempo Bioscience focuses on creating induced pluripotent stem cell-based models and proprietary biosensors to support disease modeling and drug development. They offer a variety of products, including specialized cell lines and assay reagents, along with services like custom assays and partnerships. Located in San Francisco, USA, they serve researchers and pharmaceutical companies by advancing tools for scientific innovation and medical research.
Tempo Bioscience's top competitors include CytoTronics, Kiyatec and Remedy Plan.
Tempo Bioscience offers iAstroâ„¢, TempoATPâ„¢, iCardioâ„¢, and TempoCALâ„¢.